Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Invested Capital (2016 - 2025)

Historic Invested Capital for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $334.7 million.

  • Vanda Pharmaceuticals' Invested Capital fell 3842.48% to $334.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $334.7 million, marking a year-over-year decrease of 3842.48%. This contributed to the annual value of $334.7 million for FY2025, which is 3842.48% down from last year.
  • As of Q4 2025, Vanda Pharmaceuticals' Invested Capital stood at $334.7 million, which was down 3842.48% from $466.0 million recorded in Q3 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Invested Capital peaked at $544.9 million during Q4 2023, and registered a low of $334.7 million during Q4 2025.
  • For the 5-year period, Vanda Pharmaceuticals' Invested Capital averaged around $506.7 million, with its median value being $513.5 million (2022).
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Invested Capital soared by 1230.61% in 2021, and later crashed by 3842.48% in 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Invested Capital (Quarter) stood at $504.9 million in 2021, then rose by 4.41% to $527.2 million in 2022, then increased by 3.36% to $544.9 million in 2023, then decreased by 0.26% to $543.5 million in 2024, then tumbled by 38.42% to $334.7 million in 2025.
  • Its last three reported values are $334.7 million in Q4 2025, $466.0 million for Q3 2025, and $486.3 million during Q2 2025.